Logo

Affibody and NCI to Develop Molecular In Vivo Imaging Agents

Nov 08, 2005

NEW YORK, Nov. 8 (GenomeWeb News) - Affibody and the National Cancer Institute plan to co-develop conjugates with Affibody molecules to be used for in vivo imaging, the Swedish company said today.

 

The agreement combines Affibody's internally developed technology with the US National Institute of Health's conjugation systems.

 

Affibody will develop engineered Affibody molecules specific for HER2, a receptor protein sometimes over-expressed in breast and ovarian cancers. NCI will conjugate the engineered molecules with detection molecules for evaluation.

 

Additional details were not disclosed.

Breaking News
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.